Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Shares of Sangamo Therapeutics climbed after the genomic medicine company entered a licensing agreement with Eli Lilly for STAC-BBB. The stock rose 31% to 81 cents on volume of 3.1 million shares in ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

The Business Research Company Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout. LONDON, GREATER ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

Dr Reddy’s Laboratories is also working on a generic version of Wegovy. (Image/Getty) US pharma major Eli Lilly on Thursday launched its global bestseller anti-obesity and diabetes drug Mounjaro ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...